METHOD OF CORRECTING ENDOTHELIAL DYSFUNCTION WITH TRIMETAZIDINE IN AN ADMA-LIKE MODEL OF PREECLAMPSIA Russian patent published in 2019 - IPC A61M31/00 A61K31/495 A61P15/00 G09B23/28 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to experimental pharmacology, and can be used for correction of endothelial dysfunction in ADMA-like model of preeclampsia. That is ensured by intraperitoneal introduction of L-nitro-arginine-methyl ester 25 mg/kg in a pre-eclampsia model in Wistar rats for 7 days every day from 14th to 20th day of pregnancy. Against the background of simulated pathology, intragasting is administered through a probe of trimetazidine daily single dose of 6 mg/kg from 14 to 20 days of pregnancy.

EFFECT: method provides effective correction of simulated state, reliable reduction of endothelial dysfunction coefficient, correction of systolic and diastolic arterial pressure due to pronounced anti-ischemic and antioxidant action of trimetazidine.

1 cl, 1 tbl, 1 ex